Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Eli Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after over three years of treatment.

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 </str ...

There’s progress in the battle against Alzheimer’s and, while there’s still no cure, new tests and treatments are presenting ...

Eisai and Biogen's Alzheimer's drug Leqembi continues to show promise in slowing disease progression, with no new safety issues observed over four years. The injectable form of Leqembi is under U.S.

The drug is called Leqembi, and it removes plaques in the brain that are associated with Alzheimer's. After about 18 months, ...

Saudi Arabia’s SFDA has approved Leqembi (lecanemab), the Kingdom’s first Alzheimer’s treatment. This innovative drug slows ...

The Alzheimer’s drug Leqembi, the first medicine proven to slow the course of the disease, may be able to be given as a set of two weekly shots at home, a study from drugmaker Eisai suggests ...

Leqembi is not a cure, but it is the first drug shown to slow the progression of Alzheimer's disease. It first received an accelerated approval from the FDA earlier this year.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced ...